Drug intelligence / Profile preview

sacituzumab

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Sacituzumab is a humanized monoclonal antibody that specifically targets the Tumor-associated calcium signal transducer 2 (Trop-2) receptor. It serves as the antibody component in antibody-drug conjugates (ADCs), such as sacituzumab govitecan and sacituzumab tirumotecan, facilitating the targeted delivery of cytotoxic payloads to Trop-2-expressing cancer cells.

Other names: hRS7hRS-7hRS 7

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on sacituzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sacituzumab.

Explore the full profile